In session 14 of the FIGON-Dutch Medicines Days, day 2, experts will share their insight knowledge on a series of aspects relevant for designing a successful repurposed drug program with a viable business case in mind, which are necessary to keep in mind in order to increase the odds of indeed finally making the drug available for patients in need thereof.  In session 14, light will shed on:

(1) clinical trial design for drug repurposing, 
(2) current and desired improved drug pricing- and reimbursement systems relating to drug repurposing, 
(3) pharmaceutical legislation of the European Union including proposed reform thereof in part in favour of drug repurposing programs, 
(4) registration requirements for a repurposed drug, 
(5) the benefits that patenting can provide for a drug repurposing program regarding staying in control when a pricing- and reimbursement scheme for example is established, and
(6) details of importance for an attractive drug repurposing program worthwhile for taking the risk to invest.

Chair: Barend Bouma (NLO)

Speakers: Bianca Pauly (3D-PharmXchange), Benien Vingerhoed (FAST), Jaap Mannaerts (NLO), Geert Corstens (Oost NL)

Selected Abstract Presenter: Ana I Casas (University Hospital Essen)

FIGON Partners: FAST & CBG